The purpose of the study is to evaluate how effective, safe, and tolerable this oral solution is for relieving chronic neuropathic pain in MS patients. Participants in the study will receive either the THC:CBD oral solution or a matching placebo. The study will last for a total of 12 weeks, with the main focus on the first 4 weeks of treatment. During this time, participants will be monitored to see how their pain levels change and to ensure their safety while using the treatment.

Throughout the study, participants will have regular check-ups to assess their pain levels and overall health. The study aims to determine if the THC:CBD solution can significantly reduce pain and improve the quality of life for those living with MS-related chronic neuropathic pain. The results will help researchers understand the potential benefits of this treatment for managing pain in MS patients.

The purpose of the study is to determine if at least one dose of LY3848575 is more effective than a placebo in reducing pain. Participants in the study will receive either the medication or a placebo and will be monitored over a period to assess changes in their pain levels. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo, ensuring unbiased results.

Throughout the study, participants will be asked to rate their pain using a simple scale, and the results will help researchers understand the potential benefits of LY3848575 for people suffering from chronic neuropathic pain. The study aims to provide valuable information that could lead to new treatment options for those affected by this painful condition.

Participants in the study will receive either psilocybin capsules or a placebo. The psilocybin capsules come in two different doses: 1 mg and 25 mg. The study aims to see if psilocybin can help reduce the interference of pain with daily activities. The trial will also look at how participants feel about the treatment and any changes in their emotional and psychological well-being. The study will be conducted over a short period, with participants taking the medication orally.

The main goal of the study is to assess how feasible it is to use psilocybin as a treatment for chronic neuropathic pain caused by chemotherapy. Researchers will also gather information on how well participants tolerate the treatment and any side effects they might experience. This trial is an important step in understanding whether psilocybin could be a helpful option for managing pain in people who have undergone chemotherapy.

Participants in the study will receive one of the three treatments and will be monitored over a period of time to assess the effectiveness of the treatment in reducing pain. The main assessment will take place 8 weeks after the treatment begins. During the study, participants will be asked to rate their pain levels using a simple scale from 0 to 10, where 0 means no pain and 10 means the worst pain imaginable. This self-assessment helps to understand how the treatment is working from the participant’s perspective.

Throughout the study, additional evaluations will be conducted at various intervals to track changes in pain levels and any side effects that may occur. The study aims to provide valuable information on which treatment might be most effective for managing chronic pain after a mastectomy, offering hope for better pain management options in the future.

Participants in the study will be randomly assigned to receive either lacosamide or duloxetine. The study will last for a period of eight weeks, during which the effectiveness of the medications in reducing pain will be observed. Participants will take the medication orally, and their pain levels will be monitored throughout the study. The study aims to determine if lacosamide is as effective as duloxetine in managing pain caused by chemotherapy-induced neuropathy.

In addition to assessing pain relief, the study will also evaluate patient satisfaction with the treatment and any side effects experienced. This information will help in understanding the overall benefits and potential drawbacks of each medication for individuals suffering from chemotherapy-induced neuropathy. The findings from this study could provide valuable insights into better pain management strategies for patients who have undergone chemotherapy.

Participants in the study will be randomly assigned to receive either the Qutenza patch or a low-dose capsaicin patch. The study will last for several weeks, during which participants will have their pain levels monitored regularly. The main goal is to observe changes in pain intensity from the start of the study to the end of the 12-week period. The study will also look at any side effects that may occur during the treatment.

The trial is designed to help understand how well Qutenza works in reducing pain and to ensure it is safe for use. Participants will be closely monitored throughout the study to gather information on how the treatment affects their pain and overall health. This research is important for developing better treatments for people who suffer from post-surgical neuropathic pain.

The purpose of the study is to analyze sleep and its detailed structure in patients with neuropathic pain, both with and without significant sleep disturbances, before and during treatment with pregabalin. Participants will be monitored for changes in their sleep stages, brain activity, and body temperature during sleep. The study will also explore how sleep disturbances relate to brain connectivity and other brain features using techniques like fMRI, which is a type of brain scan that measures brain activity by detecting changes associated with blood flow.

Throughout the study, participants will undergo various assessments, including a one-night sleep study called ambulatory polysomnography, which records brain waves, oxygen levels, heart rate, and breathing during sleep. Additionally, the study will use devices like the OURA-ring and iButton to track sleep patterns and body temperature over a week. The study is expected to provide valuable insights into how pregabalin can help manage pain and improve sleep quality in patients with neuropathic pain.

Participants in the study will receive either the Clinican THC 2% oil or a placebo, which looks like the treatment but does not contain the active ingredient. The study is designed to compare the effects of the oil with the placebo to see if there is a significant difference in pain relief. The study will also explore how different groups of patients respond to the treatment, which may help identify which patients benefit the most from the oil.

Throughout the study, participants will be asked to take the treatment under the tongue, a method known as sublingual use. The study will last for a period of time, during which participants will regularly report their pain levels and other experiences. This information will help researchers determine the effectiveness of the treatment and gather insights into its impact on quality of life, sleep, anxiety, and other factors related to chronic neuropathic pain.

Participants in the study will receive either the NT 201 injections or placebo injections. The study will monitor changes in pain levels over several weeks to determine the effectiveness of the treatment. The trial is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo, ensuring unbiased results. The study will also track any side effects that may arise during the treatment period.

The purpose of this trial is to gather evidence on whether NT 201 can provide relief for those suffering from moderate to severe chronic neuropathic pain. By comparing the effects of NT 201 to a placebo, researchers hope to establish its potential as a treatment option for managing this type of pain. Participants will be closely monitored throughout the study to ensure their safety and to collect accurate data on the treatment’s impact on their pain levels.

Participants in the study will receive either the capsaicin patch or a placebo patch. The patches are applied to the skin, and the study will monitor changes in pain levels over a period of four months. The main goal is to see if the capsaicin patch can improve the symptoms of neuropathic pain, as measured by a specific questionnaire called the Neuropathic Pain Symptom Inventory (NPSI). This questionnaire helps to assess the severity and impact of the pain on daily life.

Throughout the study, participants will be closely monitored for any side effects or changes in their health. This includes regular check-ups and phone calls to ensure their well-being. The study aims to provide valuable information on whether the capsaicin patch can be an effective treatment option for young people suffering from chronic neuropathic pain after surgery or injury.